Main Industry
Biotechnology
Main Product/Service
i-OBM develops innovative drug formulations using existing active ingredients, focusing on enhancing efficacy, reducing side effects, and extending drug half-life through advanced delivery systems. Their technologies include chelating complex micelles, tr
The content above was translated by Ai
Founded Year
2011
Unified Business No.
29184891
Status
Active
Number of Employees
0
Total Paid-in
Capital
668,080,000 (NT$)
Location of Company
Taiwan
, Tainan City
Exit Status
Emerging Stock Exchange(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Original BioMedical focuses on developing new drug forms, dosages, and indications without introducing new active ingredients. Their platform can modify a drug’s half-life, enhance efficacy, and reduce side effects, enabling repurposing of existing drugs to shorten development time and revive near-failure compounds. They handle lab-scale synthesis, purification, method and dosage form development, and preclinical testing, while formal preclinical and clinical production is conducted at cGMP-certified manufacturing facilities.
The content above was translated by Ai
